<?xml version="1.0" encoding="UTF-8"?>
<app-group>
 <app id="app1-biomolecules-10-01148">
  <title>Supplementary Materials</title>
  <p>The following are available online at 
   <uri xlink:href="https://www.mdpi.com/2218-273X/10/8/1148/s1" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.mdpi.com/2218-273X/10/8/1148/s1</uri>, Characteristics of synthesized compounds, Figure S1: Anti-HIV-1 activity of 3-carboxyacylbetulin phosphate and BVM in the tested concentration range, Figure S2: Cytotoxicity of betulin phosphate 2–5 in the tested concentration range, Table S1: Selected physicochemical properties of the compounds 2–5, Table S2: Scoring functions of the tested compounds (SARS-Cov-2 proteins), Figure S3: The lowest-energy docking poses of SARS-Cov-2 Mpro protein complexes with BVM (A) and betulinic acid (B), Figure S4: Visualization of interaction between BVM (A) and compound 4 (B) with SARS-Cov-2 RdRp, Figure S5: Docking pose of SARS-Cov-2 E protein complexes with BVM (A) and compound 6 (B), Figure S6: Visualization of interaction between betulinic acid (A) and BVM (B) with SARS-Cov-2 spike protein monomer, Figure S7: RMSD for atoms of protein (Mpro, RdRp, E) backbones (left) and ligands (right), Figure S8: RMSD for atoms of S protein backbones (left) and ligands (right), Figure S9: RMSD for atoms of E protein backbones without terminal residues, Table S3: Interactions of tested compounds with SARS-CoV-2 proteins (References [
   <xref rid="B59-biomolecules-10-01148" ref-type="bibr">59</xref>,
   <xref rid="B60-biomolecules-10-01148" ref-type="bibr">60</xref>] are cited in the supplementary materials).
  </p>
 </app>
</app-group>
